Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $18.30.

A number of brokerages recently issued reports on YMAB. Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, March 5th. Truist Financial cut their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Wedbush reiterated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright decreased their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Bank of America dropped their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th.

Y-mAbs Therapeutics Trading Up 3.3 %

Shares of NASDAQ:YMAB opened at $4.69 on Friday. The firm’s 50 day moving average is $5.06 and its two-hundred day moving average is $8.48. The firm has a market capitalization of $212.07 million, a P/E ratio of -8.69 and a beta of 0.71. Y-mAbs Therapeutics has a 52 week low of $3.86 and a 52 week high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. During the same period in the previous year, the firm earned ($0.02) EPS. Analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 22.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the business. State Street Corp lifted its position in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Barclays PLC boosted its stake in shares of Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares during the period. Geode Capital Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after acquiring an additional 47,846 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Y-mAbs Therapeutics in the third quarter worth $267,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after acquiring an additional 2,854 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.